The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.
The GlaxoSmithKline-Pfizer-Shionogi joint venture scored an FDA approval in August.
BMS is giving up its stake of the AstraZeneca diabetes joint venture for $2.7 billion up front, and future milestone payments.
Glaxo shakes up China division, Teva and Lonza break up their biosimilars pact, and FDA's breakthrough designation speeds review but not international and payer uptake.
India bans sales of Takeda's Actos; Takeda make a $10-million milestone payment to Sucampo; and Pfizer Consumer Care says Advil is the official pain reliever of Tough Mudder.
Interpublic's McCann HumanCare and Casanova Pendrill hope to sell pharmas on deeper engagement with Hispanic audiences through a joint venture dubbed HumanCareHSP
Time Inc. targeted media brand focuses on pharma; Takeda and Amylin call it quits on obesity partnership; PricewaterhouseCoopers builds regulatory intelligence unit
When Pfizer's US Enbrel sales force gives way to Amgen's in July, reps risk layoff if they don't get picked up by Amgen or re-assigned to Pfizer's new JAK inhibitor.
Teva is partnering with Procter & Gamble in an OTC drug marketing joint venture that will boast annual sales of more than $1 billion -- and which could ultimately be worth four times that, the companies say.
Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.